Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Application of Nanocarrier Systems for the Delivery of Bioactive Natural...
share announcement

Application of Nanocarrier Systems for the Delivery of Bioactive Natural Products and Derivatives Thereof

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 4263

Special Issue Editors

Dr. Valeria Patricia Sülsen

E-Mail Website
Guest Editor
1. Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
2. Institute of Chemistry and Metabolism of Drugs (IQUIMEFA), University of Buenos Aires—National Scientific and Technical Research Council, Buenos Aires, Argentina
Interests: neglected diseases; antimicrobial activity; natural compounds; plant extracts; terpenoids; flavonoids; Asteraceae
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Maria Do Céu Costa

E-Mail Website
Guest Editor
1. CBIOS-Centro de Biociências/The Biosciences Research Center, ECTS-School of Health Sciences and Technologies, Lusófona University, Campo Grande, 376, 1749-024 Lisboa, Portugal
2. IPLUSO/NICiTeS-ERISA-Escola Superior de Saúde Ribeiro Sanches, Rua do Telhal aos Olivais, 8-8ª, 1900-693 Lisboa, Portugal
Interests: natural products chemistry; structure-activity relationships
Prof. Dr. Constantinos Athanassopoulos

E-Mail Website
Guest Editor
Department of Chemistry, University of Patras, GR-26504 Patras, Greece
Interests: small organic molecules; natural products; anticancer and antibacterial agents; multitarget inhibitors; hybrids; bioconjugates
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since ancient times, natural products have been used as medicines for the treatment of several illnesses. In this sense, the isolation and identification of bioactive natural compounds have played a crucial role in the drug discovery process.

Natural molecules as well as their derivatives have been used for the development of novel treatments for a variety of diseases, with cancer and infectious diseases being among the most noteworthy. Although bioactive natural compounds have many advantages, such as a low molecular weight, variety of structures and chiral centers that allow for interactions with biological targets, many of them also have drawbacks related to their poor solubility, permeability and/or stability in biological mediums.

At present, researchers are putting more efforts in developing a Novel Drug Delivery System (NDDS) for the effective and targeted delivery of old, well-established molecules to increase safety and efficacy and to reduce the needed dose, instead of inventing new drug molecules.

In recent years, nanotechnology has made great progress in the development of carriers for the transportation of drugs. These systems are especially of interest for natural compound delivery, since they can overcome their limitations by improving pharmacokinetic properties and the arrival to the site of action.

This Special Issue will cover aspects related to the application of nanotechnology systems for the delivery of natural products as potential therapeutic treatments for acute and chronic diseases. Submissions, including research papers as well as mini-reviews and review articles, will be considered.

Prof. Dr. Valeria Patricia Sülsen
Prof. Dr. Maria Do Céu Costa
Prof. Dr. Constantinos Athanassopoulos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • nanocarriers
  • natural compounds
  • novel drug delivery (NDDS)
  • target delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

28 pages, 5820 KiB  
Article
Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1
by Chuda Chittasupho, Sonthaya Umsumarng, Kamonwan Srisawad, Punnida Arjsri, Rungsinee Phongpradist, Weerasak Samee, Wipawan Tingya, Chadarat Ampasavate and Pornngarm Dejkriengkraikul
Pharmaceutics 2024, 16(6), 751; https://doi.org/10.3390/pharmaceutics16060751 - 2 Jun 2024
Cited by 1 | Viewed by 1175
Abstract
The COVID-19 pandemic, caused by SARS-CoV-2, poses a significant global health threat. The spike glycoprotein S1 of the SARS-CoV-2 virus is known to induce the production of pro-inflammatory mediators, contributing to hyperinflammation in COVID-19 patients. Triphala, an ancient Ayurvedic remedy composed of dried [...] Read more.
The COVID-19 pandemic, caused by SARS-CoV-2, poses a significant global health threat. The spike glycoprotein S1 of the SARS-CoV-2 virus is known to induce the production of pro-inflammatory mediators, contributing to hyperinflammation in COVID-19 patients. Triphala, an ancient Ayurvedic remedy composed of dried fruits from three plant species—Emblica officinalis (Family Euphorbiaceae), Terminalia bellerica (Family Combretaceae), and Terminalia chebula (Family Combretaceae)—shows promise in addressing inflammation. However, the limited water solubility of its ethanolic extract impedes its bioavailability. In this study, we aimed to develop nanoparticles loaded with Triphala extract, termed “nanotriphala”, as a drug delivery system. Additionally, we investigated the in vitro anti-inflammatory properties of nanotriphala and its major compounds, namely gallic acid, chebulagic acid, and chebulinic acid, in lung epithelial cells (A549) induced by CoV2-SP. The nanotriphala formulation was prepared using the solvent displacement method. The encapsulation efficiency of Triphala in nanotriphala was determined to be 87.96 ± 2.60% based on total phenolic content. In terms of in vitro release, nanotriphala exhibited a biphasic release profile with zero-order kinetics over 0–8 h. A549 cells were treated with nanotriphala or its active compounds and then induced with 100 ng/mL of spike S1 subunit (CoV2-SP). The results demonstrate that chebulagic acid and chebulinic acid are the active compounds in nanotriphala, which significantly reduced cytokine release (IL-6, IL-1β, and IL-18) and suppressed the expression of inflammatory genes (IL-6, IL-1β, IL-18, and NLRP3) (p < 0.05). Mechanistically, nanotriphala and its active compounds notably attenuated the expression of inflammasome machinery proteins (NLRP3, ASC, and Caspase-1) (p < 0.05). In conclusion, the nanoparticle formulation of Triphala enhances its stability and exhibits anti-inflammatory properties against CoV2-SP-induction. This was achieved by suppressing inflammatory mediators and the NLRP3 inflammasome machinery. Thus, nanotriphala holds promise as a supportive preventive anti-inflammatory therapy for COVID-19-related chronic inflammation. Full article
(This article belongs to the Special Issue Application of Nanocarrier Systems for the Delivery of Bioactive Natural Products and Derivatives Thereof)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 2845 KiB  
Review
Therapeutic Applications of Nanoformulated Resveratrol and Quercetin Phytochemicals in Colorectal Cancer—An Updated Review
by Dhanalekshmi Unnikrishnan Meenakshi, Gurpreet Kaur Narde, Alka Ahuja, Khalid Al Balushi, Arul Prakash Francis and Shah Alam Khan
Pharmaceutics 2024, 16(6), 761; https://doi.org/10.3390/pharmaceutics16060761 - 4 Jun 2024
Cited by 3 | Viewed by 1590
Abstract
Natural compounds such as polyphenols play several positive roles in maintaining the oxidative and inflammatory capacity of cells, which leads to their potential use as anticancer therapeutics. There is promising evidence for the in vitro and in vivo anticancer activity of many polyphenols, [...] Read more.
Natural compounds such as polyphenols play several positive roles in maintaining the oxidative and inflammatory capacity of cells, which leads to their potential use as anticancer therapeutics. There is promising evidence for the in vitro and in vivo anticancer activity of many polyphenols, including resveratrol and quercetin, specifically in the treatment of colorectal cancer (CRC). There is a clear association between resveratrol and quercetin in interfering with the mechanistic pathways involved in CRC, such as Wnt, P13K/AKT, caspase-3, MAPK, NF-κB, etc. These molecular pathways establish the role of resveratrol and quercetin in controlling cancer cell growth, inducing apoptosis, and inhibiting metastasis. The major bottleneck in the progression of the use of resveratrol and quercetin as anticancer therapeutics is their reduced bioavailability in vivo because of their rapid metabolism in humans. Recent advancements in various nanotechnological formulations are promising for overcoming these bioavailability issues. Various nanoformulations of resveratrol and quercetin have shown an optimistic impact on reducing the solubility and improving the stability of resveratrol and quercetin in vivo. A combinatorial approach using nanoformulations of resveratrol with quercetin could potentially increase the impact of resveratrol in controlling CRC cell proliferation. This review discusses the mechanism of resveratrol and quercetin, the two bioactive polyphenolics, in colon cancer, with an emphasis on various types of nanoformulations of the two molecules targeting colon cancer. It also explores the synergistic effect of combining resveratrol and quercetin in various nanoformulations, targeting colon cancer. This research delves into the enhanced pharmacokinetics and potential chemotherapeutic benefits of these bioactive polyphenolics when used together in innovative ways. Full article
(This article belongs to the Special Issue Application of Nanocarrier Systems for the Delivery of Bioactive Natural Products and Derivatives Thereof)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop